EUVIMEDEUVIMED entdecken
Crossref

Prognostic Significance of Crooke Cell Pituitary Neuroendocrine Tumor/Adenoma Subtype Status in Time to Recurrence of Corticotroph Tumors

Georgios A. Maragkos, Lena Young, Vince L. Popolizio, Sean Runge, Angelica Fuentes, Georgios Mantziaris, Michael P. Catalino, Gregory K. Hong, Mary-Lee Vance, Beatriz Lopes, John Jane

Journal of Neurological Surgery Part B: Skull Base · 01.02.2024 · 85 (S 01 S 01) · S1-S398

DOI: 10.1055/s-0044-1780050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 01.02.2024. Verfasst von Georgios A. Maragkos und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Crooke cell adenomas (CCA) are a rare subtype of corticotroph pituitary neuroendocrine tumor (PitNET)/adenoma, either causing Cushing’s disease or clinically silent. CCAs are associated with more aggressive clinical behavior, however, prognostic data are limited due to their rarity. It is unclear whether the biologically aggressive phenotype of CCA leads to higher prevalence of cavernous sinus tumor invasion and postoperative tumor residual, necessitating adjuvant radiotherapy for local tumor control.

Methods

A single-institution retrospective chart review captured patients with corticotroph PitNET/adenomas who underwent resection between 2005 and 2023. Both patients with Cushing’s disease and patients with silent corticotrophs were included. Patients without pathology slides available for Neuropathology re-review were excluded. CCAs were compared to non-CCA corticotroph PitNET/adenomas regarding the primary outcome of time-to-recurrence (TTR). Recurrence was defined as postoperative radiographic tumor recurrence/growth, or biochemical Cushing’s recurrence/emergence. Time-to-event analysis was conducted using Kaplan–Meier curves and multivariable Cox regression, to evaluate the association between CCA status and TTR. Missing values were handled using list-wise deletion on multivariable regression.

Results

A total of 188 patients with corticotroph PitNETs/adenomas were identified. On pathology review, 27 (14.4%) were classified as CCA, and 161 (85.6%) as non-CCA. Mean (standard deviation) age was 44 ± 16 years for the CCA group and 46 ± 15 years for the non-CCA ( p = 0.55). Among the CCA group, 51.9% of patients were female, while 73.3% were female in the non-CCA group ( p = 0.024). In the CCA cohort, 84% of tumors were macroadenomas vs 61.9% of non-CCAs ( p = 0.032), and 56.0% of CCAs demonstrated cavernous sinus invasion vs 32.5% of non-CCAs ( p = 0.023). Cushing’s disease was present preoperatively in 55.6% of CCA and 56.3% of non-CCA patients ( p = 0.95), while the rest harbored silent corticotroph PitNET/adenomas. Postoperatively, 57.7% of CCA patients had residual tumor vs 30.6% of non-CCAs ( p = 0.007), and 81.6% of all patients with preoperative Cushing’s disease achieved biochemical remission. In the follow-up period, 42.3% of CCA and 20.6% of non-CCA patients received adjuvant radiation. Median radiographic follow-up was 52 months (interquartile range: 15–109). Radiographic recurrence or growth was found in 24.5% of patients (33.3% CCAs, 34.2% non-CCAs, p = 0.93), after a median of 44 months (26–73). On multivariable Cox regression (160 patients included), CCA status was not associated with TTR ( p = 0.56, [ Fig. 1 ]), when controlling for preoperative Cushing’s disease status (hazard ratio [HR] = 2.86, p = 0.001), female sex (HR = 0.48, p = 0.024), cavernous sinus invasion (HR = 3.39, p < 0.001), and adjuvant radiation (HR = 0.16, p < 0.001). Fig. 1 Conclusions: While CCAs are more likely to present with larger tumors and cavernous sinus invasion, after controlling for these and other known prognostic factors, CCAs did not demonstrate a higher likelihood to recur. Further investigation is warranted regarding whether CCAs have higher recurrence rates due to a propensity to invade the cavernous sinus in the first place, or a biologically more aggressive phenotype. Publication History Article published online: 05 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Maragkos, G. A., Young, L., Popolizio, V. L., Runge, S., Fuentes, A., Mantziaris, G., Catalino, M. P., Hong, G. K., Vance, M., Lopes, B., & Jane, J. (2024). Prognostic Significance of Crooke Cell Pituitary Neuroendocrine Tumor/Adenoma Subtype Status in Time to Recurrence of Corticotroph Tumors. Journal of Neurological Surgery Part B: Skull Base, 85(S 01 S 01), S1-S398. https://doi.org/10.1055/s-0044-1780050

Vancouver

Maragkos GA, Young L, Popolizio VL, Runge S, Fuentes A, Mantziaris G, et al. Prognostic Significance of Crooke Cell Pituitary Neuroendocrine Tumor/Adenoma Subtype Status in Time to Recurrence of Corticotroph Tumors. Journal of Neurological Surgery Part B: Skull Base. 2024;85(S 01 S 01):S1-S398. doi:10.1055/s-0044-1780050

BibTeX
@article{Maragkos2024,
  author = {Maragkos, Georgios A. and Young, Lena and Popolizio, Vince L. and Runge, Sean and Fuentes, Angelica and Mantziaris, Georgios and Catalino, Michael P. and Hong, Gregory K. and Vance, Mary-Lee and Lopes, Beatriz and Jane, John},
  title = {Prognostic Significance of Crooke Cell Pituitary Neuroendocrine Tumor/Adenoma Subtype Status in Time to Recurrence of Corticotroph Tumors},
  journal = {Journal of Neurological Surgery Part B: Skull Base},
  year = {2024},
  volume = {85},
  number = {S 01 S 01},
  pages = {S1--S398},
  doi = {10.1055/s-0044-1780050}
}
Kostenlos starten →